Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cocktail of 4 immune drugs takes on tough colorectal cancer

NCT ID NCT06149481

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) to see if they can shrink or control metastatic colorectal cancer that has spread after standard treatments. About 60 adults aged 18 and older will receive the drugs for up to 2 years, with regular checkups and two tumor biopsies. The goal is to find a safe and effective way to boost the immune system against this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.